We have previously reported that ET-resistant breast cancers exhibit enhanced expression of the glutamate and aspartate transporter SLC1A2, which supports the metabolic demands sustaining tumor aggressiveness [5]. This evidence concerns the gene SLC1A2 and breast cancer.